RAF-independent MEK mutations drive refractory histiocytic neoplasms but respond to ERK inhibition

Key Points

• ERK inhibition significantly reduces symptoms in cases of refractory histiocytic neoplasms, benefiting patients with MEK mutations.
• MEK mutations were identified in all refractory cases, indicating a strong link to disease progression.
• Analysis conducted on patient samples revealed the effectiveness of targeting RAF-independent pathways with ERK inhibitors.
• Findings may lead to new treatment strategies for patients with hard-to-treat histiocytic neoplasms and highlight potential molecular targets.